Affordable Access

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.

Authors
  • Rodgers, G P
  • Dover, G J
  • Uyesaka, N
  • Noguchi, C T
  • Schechter, A N
  • Nienhuis, A W
Type
Published Article
Journal
The New England journal of medicine
Publication Date
Jan 14, 1993
Volume
328
Issue
2
Pages
73–80
Identifiers
PMID: 7677965
Source
Medline
License
Unknown

Abstract

Intravenous recombinant erythropoietin with iron supplementation alternating with hydroxyurea elevates fetal-hemoglobin and F-cell levels more than hydroxyurea alone. Such increases decrease intracellular polymerization of hemoglobin S and improve the overall rheologic characteristics of erythrocytes. A reduced dosage of hydroxyurea alternating with erythropoietin may prove less myelotoxic than hydroxyurea given daily or in pulsed-dose regimens. It may also increase levels of fetal hemoglobin in patients with sickle cell disease who have not been helped by hydroxyurea alone.

Report this publication

Statistics

Seen <100 times